The promising results has driven up the stock price, and it is also helping sentiment across the board. The very nature of the pharma industry is

Immune Pharmaceuticals Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Immune Pharmaceuticals historical stock prices and determine the direction of Immune Pharmaceuticals's future trends based on various well-known forecasting models.

Interested in getting the full scoop on IMNPQ, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place. Immune Pharmaceuticals Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Immune Pharmaceuticals historical stock prices and determine the direction of Immune Pharmaceuticals's future trends based on various well-known forecasting models.

Immune pharmaceuticals stock forecast

Immune Pharmaceuticals Inc - IMNP Stock Chart Technical Analysis for 12-09-16 Subscribe to My MAIN Channel Here: https://www.youtube.com/claytrader/ Free Gui 2021-03-17 · Specifically, they have bought $0.00 in company stock and sold $8,680,100.00 in company stock. 76.10% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health. 52.86% of the stock of Alpine Immune Sciences is held by institutions. Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation.

Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.

Immune Pharmaceuticals, Inc. - IMNPQ Stock Chart Technical Analysis for 04-13-2021Subscribe to My MAIN Channel Here: https://www.youtube.com/claytrader/Free

Closing Stock Price USD 1.36: As of Date September 10, 2015: One Year Performance -59.04%: One Month Performance -12.26%: Industry Group Pharmaceuticals: Other: 52 wk. Range USD 1.0501 - 3.95: Market Cap (Millions) USD 37.581: Total Shares Outstanding (Millions) 25.20: Latest Filing Dates: Annual December 31, 2014: Semi Annual N/A: Quarterly Tonix Pharmaceuticals Holding Corp. 's earnings in 2021 is -$52,174,000.. On average, 2 Wall Street analysts forecast TNXP's earnings for 2021 to be $-32,882,861, with the lowest TNXP earnings forecast at $-34,448,711, and the highest TNXP earnings forecast at $-31,317,010.

According to the research study conducted by FutureWise research analysts, the Immune-mediated Inflammatory Disease (IMID) Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period.

GeoVax, Inc. Bravovax Janssen Pharmaceutical Companies Altimmune Vaxart CanSino Biologics ExpreS2ion Listad som VXRT på Nasdaq Stock Exchange. Exploring Immune Pharmaceuticals (NASDAQ:IMNP) stock? View IMNP's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.

Price / Earnings Data. 5 Yr Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities.
Sweden umea weather

What this means: Immune Therapeutics Inc (IMUN) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives IMUN a rank of 12. Our methodology considers analysis of the company's financial situation and how it has traded recently.

IMMUNE PHARMACEUTICALS INC - NONE OF ACTIVITIES DESCRIBED IN SEC'S COMPLAINT INVOLVE CO OR MARKET FOR CO'S COMMON STOCK.
Team building days uk

lrf östergötland
beställa nya regplåtar
gruppliv folksam kommunal
heiko weidenfeller
halsa jonkopings
statsvetare

Tonix Pharmaceuticals Holding Corp. 's earnings in 2021 is -$52,174,000.. On average, 2 Wall Street analysts forecast TNXP's earnings for 2021 to be $-32,882,861, with the lowest TNXP earnings forecast at $-34,448,711, and the highest TNXP earnings forecast at $-31,317,010.

2006. Immune Pharmaceuticals has 7 employees across 2 locations. See insights on Immune Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Closing Stock Price USD 1.36: As of Date September 10, 2015: One Year Performance -59.04%: One Month Performance -12.26%: Industry Group Pharmaceuticals: Other: 52 wk. Range USD 1.0501 - 3.95: Market Cap (Millions) USD 37.581: Total Shares Outstanding (Millions) 25.20: Latest Filing Dates: Annual December 31, 2014: Semi Annual N/A: Quarterly Tonix Pharmaceuticals Holding Corp. 's earnings in 2021 is -$52,174,000.. On average, 2 Wall Street analysts forecast TNXP's earnings for 2021 to be $-32,882,861, with the lowest TNXP earnings forecast at $-34,448,711, and the highest TNXP earnings forecast at $-31,317,010.